Q-Med's Durolane Knee Therapy, DePuy's CoMplete Hip Go To Panel
This article was originally published in The Gray Sheet
Executive Summary
FDA's Orthopedic and Rehabilitation Devices panel will meet Aug. 19 to assess Q-Med's PMA application for its Durolane single-injection, hyaluronic acid-based treatment for knee osteoarthritis
You may also be interested in...
FDA Panel Endorses Genzyme’s Synvisc-One Knee Therapy
FDA's Orthopedic and Rehabilitation Devices advisory panel voted unanimously last week to recommend approval of Genzyme's PMA supplement for a single-dose version of its hyaluronic acid-based osteoarthritis knee therapy
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.